案件查詢
| 計畫編碼 | 計畫主持人 | 研究護理師 | 癌別 | 計畫名稱 | 收案條件 | 藥物 | 附件檔 |
| D8990C00001 | 鍾奇峰 | 徐禾姍#1678 吳星慧#1676 | 其他 | 一項模組化第 I／IIa 期、開放性、多中心試驗，評估 AZD5335 遞增劑量單一療法與合併抗癌藥物使用於實體腫瘤參與者的安全性、耐受性、藥動學和初步療效 | Ovarian Cancer Lung cancer |
AZD5335 AZD5335 +AZD5305 | 下載 |
| D8991C00001 | 鍾奇峰 | 楊琇帆#1689 馮晴＃1670 | 婦癌 | 一項隨機、開放標籤 III 期研究，比較 AZD5335 與 Mirvetuximab Soravtansine 在 FRα-high 中的療效以及 AZD5335 與醫師選擇化療上皮性卵巢癌患者中的療效 (TREVI-OC-01) | 1.high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer. 2. must have platinum-resistant disease: (a) Participants who have only had one prior line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response (CR or PR) and then progressed between > 3 months and ? 6 months after the date of the last dose of platinum. (b) Participants who have received 2 or 3 lines of platinum therapy must have progressed ? 6 months after the date of the last dose of platinum. 3. must have received at least one, but no more than 3, prior systemic lines of anti-cancer therapy |
AZD5335 | 下載 |
| DS6000-109 | 鍾奇峰 | 吳星慧#1676 | 婦癌 | 一項針對鉑抗藥性的高惡性卵巢癌、原發性腹膜癌或輸卵管癌受試者使用 CDH6 導向抗體藥物複合體 Raludotatug Deruxtecan (R-DXd) 之第 2／3 期、多中心、隨機分配試驗（在鉑抗藥性卵巢癌中評估 R-DXd 最佳劑量並於第 3 期試驗與試驗主持人選用之化學治療進行比較） | 1.Subjects with histologically or cytologically documented high-grade serous, high-grade endometrioid OVC, primary peritoneal ca, or fallopian tube ca. 2. platinum-resistant 3. 若受試者僅接受過1線鉑類治療： 3-1. 必須至少接受4個療程的鉑類治療 3-2. 鉑類Last dose 超過90天且不超過180天內出現疾病進展 4. 若受試者曾接受 2 至 4 線鉑類治療： 4-1. 必須至少接受 2 個療程的鉑類治療 4-2. 鉑類Last dose 180 天內（包含180天）出現疾病進展 5. 排除 Has clinical symptoms or radiographic evidence of intestinal obstruction. 6. 排除 Has ascites or pleural effusions that require repeated drainage (less than 4 weeks between drainages). |
DS-6000a | 下載 |
| DS7300-203 | 鍾奇峰 | 張雅雯#1687 | 其他 | 一項第 1b／2 期、泛腫瘤、開放標記試驗，旨在評估 Ifinatamab Deruxtecan (I-DXd) 用於復發性或轉移性固體腫瘤受試者的療效及安全性 (IDeate-Pantumor02) | Pathologically or cytologically documented unresectable or metastatic UC of the bladder, renal pelvis, ureter, or urethra. Subjects with histological variants are allowed if urothelial histology is predominant. Small cell/neuroendocrine tumors are not allowed even if mixed histology |
Ifinaatamab Deruxtecan (I-DXd) | 下載 |
| DS8201-793 | 陳鵬宇 | 楊琇帆#1689 | 肺癌 | 一項第 3 期、多中心、隨機分配、開放標示，在患有局部晚期無法切除或轉移性 HER2 過度表現和 PD-L1 TPS <50% 非鱗狀非小細胞肺癌之參與者，評估 Trastuzumab Deruxtecan 併用 Pembrolizumab 相較於鉑類化療併用 Pembrolizumab 作為第一線療法的試驗 (DESTINY-Lung06) | 非麟狀局部晚期無法切除 轉移性NSCLC |
Trastuzumab Deruxtecan (T-DXd; Enhertu) | 下載 |